SCHEMBL612320

SCHEMBL612320

CCCCNc1cc(-c2ccncc2)sc1C(=O)OC

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.48
MAPT P10636 6/20 0.48
ALDH1A1 P00352 3/20 0.48
LMNA P02545 2/20 0.48
HPGD P15428 3/20 0.46
KDM6B O15054 1/20 0.44
KDM4C Q9H3R0 1/20 0.44
HTT P42858 1/20 0.44
ATM Q13315 1/20 0.44
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43
PPARG P37231 1/20 0.43
NCOA2 Q15596 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KMT2A Q03164 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TP53 P04637 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL613988 0.93 KDM4E (0.50) KDM4EMAPTALDH1A1LMNAHPGD
SCHEMBL613639 0.88 KDM6B (0.52) KDM6BKDM4C
SCHEMBL612006 0.88 KDM4E (0.52) KDM4EMAPTALDH1A1LMNAHPGD
SCHEMBL614144 0.87 CDC7 (0.54) KDM6BKDM4C
SCHEMBL613270 0.82 KDM4E (0.57) KDM4EMAPTALDH1A1LMNAHPGD
SCHEMBL611071 0.80 KDM6B (0.50) KDM6BKDM4CKMT2A
SCHEMBL612007 0.80 MAPT (0.56) KDM4EMAPTALDH1A1LMNAHPGD
SCHEMBL613122 0.79 CDC7 (0.57) KDM4EALDH1A1HPGDKDM6BKDM4C
SCHEMBL613722 0.78 KDM4E (0.52) KDM4EMAPTALDH1A1LMNAHPGD
SCHEMBL24131780 0.75 NPSR1 (0.57) KDM4EMAPTALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403857-B1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2013-12-04 EP disclosed
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-16 US disclosed
EP-2403857-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2012-01-11 EP disclosed
WO-2010101302-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS CDC7, CDK7, DTYMK KDM4E 1319/4885MAPT 2979/4885ALDH1A1 1927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.